Pattern of prostatic carcinoma metastases in bones detected by bone scans using technitium99m methyl diphosphate (TC99m MDP) imaging technique

Pakistan Journal of Medical Sciences

Volumn 22, Issue 2, 2006, Pages 180-183

  Memon, Anjuman Gul ^a   Jaleel, Anila ^a   Aftab, Jawed ^a  

^a ZIAUDDIN MEDICAL UNIVERSITY   (Pakistan)

Author keywords

Bone metastases; Bone scan; Bone secondaries; Prostate cancer

Indexed keywords

MEDRONATE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BODY POSITION; BONE METASTASIS; BONE SCINTISCANNING; CANCER LOCALIZATION; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; SPINE METASTASIS; TUMOR BIOPSY;

EID: 33744489610     PISSN: 1682024X     EISSN: 1682024X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hankey BF, Feuer EJ, Clegg LX. Cancer surveillance series: interpreting trends in prostate cancer. I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst, 1999; 91: 1017-24.
2. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin, 1993; 43: 7-26.
3. Roodman GD. Mechanisms of Bone Metastases. N Eng J Med 2004; 350: 1655-64.
4. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60-67.
5. Sakr WA, Grignon DJ, Crissman JD. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8: 439-3.
6. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
7. Mundy GR. Metastases to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-93.
8. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000; 10: 159-78.
9. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol, 2001; 19: 3562-71.
10. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection: the Investigators of the American Cancer Society-National Prostate Cancer Detection Project. CA Cancer J Clin 1993; 43: 134-49.
11. Nelson WG, De Marzo AM, Isaacs WB. Prostate Cancer. N Engl J Med 2003; 349: 366-81.
12. Parkin DM, Muir CS, Whelan SL, Gao YT, Feraly J, Powell J. Cancer incidence in five continents. IARC Sci Publ 1992; 6: 120.
13. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-76.
14. Lin K, Szabo Z, Chin BB, Civelek AC. The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med 1999; 24(8): 579-82.
15. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19: 3562-71.
16. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 1997; 157: 539-43.
17. Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M. Biochemical markers for the detection of bone metastases in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 2001; 19: 45-51.
18. Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastases by prostate cancer cells in vivo. Cancer Res 1994; 54: 2372-7.
19. Rabbani SA, Desjardins J, Bell AW. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoclast-like cells. Biochem Biophys Res Commun 1990; 173: 1058-64.